Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of "Moderate Buy" by Brokerages

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $6.42.

ESPR has been the topic of a number of recent analyst reports. JMP Securities reissued a "market outperform" rating and issued a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. Needham & Company LLC reissued a "buy" rating and issued a $5.00 price target on shares of Esperion Therapeutics in a research report on Friday. The Goldman Sachs Group decreased their price objective on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Finally, HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Friday.

Esperion Therapeutics Trading Up 4.4 %

Esperion Therapeutics stock traded up $0.04 during mid-day trading on Tuesday, hitting $0.92. 4,836,984 shares of the company's stock were exchanged, compared to its average volume of 5,663,985. Esperion Therapeutics has a 1-year low of $0.82 and a 1-year high of $3.94. The stock has a 50 day moving average of $1.40 and a two-hundred day moving average of $1.96. The stock has a market cap of $182.30 million, a P/E ratio of -1.44 and a beta of 0.86.

Institutional Trading of Esperion Therapeutics

Hedge funds have recently bought and sold shares of the stock. Synergy Asset Management LLC increased its holdings in shares of Esperion Therapeutics by 3,496.3% during the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 30,138 shares during the period. Mackenzie Financial Corp increased its stake in Esperion Therapeutics by 116.1% during the fourth quarter. Mackenzie Financial Corp now owns 143,252 shares of the biopharmaceutical company's stock valued at $315,000 after acquiring an additional 76,965 shares during the period. Two Sigma Advisers LP raised its holdings in Esperion Therapeutics by 0.4% in the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock valued at $7,956,000 after acquiring an additional 16,100 shares in the last quarter. Rafferty Asset Management LLC bought a new stake in shares of Esperion Therapeutics in the 4th quarter worth approximately $82,000. Finally, ProShare Advisors LLC grew its holdings in shares of Esperion Therapeutics by 75.2% during the 4th quarter. ProShare Advisors LLC now owns 62,549 shares of the biopharmaceutical company's stock worth $138,000 after purchasing an additional 26,843 shares in the last quarter. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.